EICHORCondition: Primary Sjögren Syndrome · Sponsor: Resolve Therapeutics
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device
This description comes directly from the study's public registry record.
PatientWing https://app.patientwing.com/campaign/clinicaltrials.gov · (213) 459-2979 · studies@patientwing.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Providing written informed consent * Weight at least 45 kg * Meet the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Classification Criteria for pSS * Diagnosis in the last 30 years * Positive anti-Ro/SSA antibody test * Score of 5 or higher on the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) scale and the ESSPRI fatigue scale * Of non childbearing potential or of childbearing potential and using highly effective contraceptive measures Exclusion Criteria: * Diagnosis of any active autoimmune disease other than pSS that could affect the efficacy assessments * Uncontrolled hypothyroidism or severe fibromyalgia * New medications or change in medications in the last 4 weeks for pSS symptoms * Receipt of other prohibited medications * Apheresis or blood donation * Allergic reaction to RSLV-132 or biologic therapy * Clinically significant infection in last 30 days * Participation in another clinical study * Malignancy in last 5 years * Positive test for HIV or hepatitis * Major surgery in last 30 days or anticipated surgery during the study * Pregnancy or breast feeding * Laboratory blood tests outside of specified ranges * Other medical conditions or medications that would make the participant unsuitable
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Resolve Clinical Site | Chula Vista, California, United States | Recruiting |
| Resolve Clinical Site | Tustin, California, United States | Recruiting |
| Resolve Clinical Site | Boca Raton, Florida, United States | Recruiting |
| Resolve Clinical Site | Boynton Beach, Florida, United States | Recruiting |
| Evolution Research Center | Hialeah, Florida, United States | Recruiting |
| GNP Research | Hollywood, Florida, United States | Recruiting |
| Resolve Clinical Site | Miami, Florida, United States | Recruiting |
| Life Medical Research | Miami Gardens, Florida, United States | Recruiting |
| Resolve Clinical Site | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Tufts College | Boston, Massachusetts, United States | Recruiting |
| Resolve Clinical Site | Albuquerque, New Mexico, United States | Recruiting |
+ 12 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06440525